Finzati - Logo
IQV logo

IQVIA Holdings Inc.

IQV • Medical - Diagnostics & Research
$267.77
— 0.00 (0.00%)
EarningsLatest report: Jun 30, 2026
BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.
Market Cap
$45.15B
Growth
7.7%
Cash Flow
5/5
Trend
Stable
Evidence
Positive revenue growth · 7.0%Positive free cash flow · 11.93Consistent free cash flow · 5/5High debt level · 2.49Weak liquidity · 0.75
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$267.77
Change0.00%
Shares Out168.60M
Market Cap$45.15B
Enterprise Value$59.07B
52W Range154.50 - 251.35
Beta1.20
P/E32.83
P/S2.66
P/B7.32
P/FCF14.73
EV/Sales3.48

Investment DNA

How strong this company looks for long-term investors

66
out of 100
Business Quality
Margins, moat, returns
68/100
Financial Strength
Debt, cash, stability
28/100
Growth Potential
Revenue and expansion
56/100
Price Attractiveness
Cheap or expensive today
63/100
Why this score▼
Positive revenue growth · 7.0%Positive free cash flow · 11.93Consistent free cash flow · 5/5High debt level · 2.49Weak liquidity · 0.75

Analyst view

Analyst sentiment and price target

IQV
Analyst sentiment
Based on 45 analyst votes · 2026-09-05
90/100
Bullish
Bullish
37
Hold
7
Bearish
1
Price Target
2026-07-30
Low
$185.00
Mean
$234.50
Median
$240.00
High
$287.00

Company Overview

IPO: 5/9/2013
Industry: Medical - Diagnostics & Research
P/B i: 7.32
Debt / Equity i: 2.49
Operating Margin: 14.02%
Net Margin: 8.34%
ROE i: -
ROIC: -

Financial Health

Score6 / 20
Debt / Equity: 2.49
Current Ratio: 0.75
Quick Ratio: 0.75
Status: Weak

Warnings

  • High debt level
  • Weak Liquidity
  • Weak quick ratio

Insider Transactions

Recent executive and insider activity

DANHAKL JOHN G
Transaction: 07/14/2026
BUY
Change
+160
Price
Not reported
Filing
07/16/2026
Type
BUY
Fasano Jim
Transaction: 07/14/2026
BUY
Change
+195
Price
Not reported
Filing
07/16/2026
Type
BUY
GOGGINS COLLEEN A
Transaction: 07/14/2026
BUY
Change
+183
Price
Not reported
Filing
07/16/2026
Type
BUY